The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review

Abstract

Background: Epidemiological studies revealed there is a difference in susceptibility to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of differences in gender with age and males being more inflicted. There is a clear indication that deaths caused by coronavirus disease 2019 (COVID-19) in males appeared at a higher rate than females across 35 nations. The implication of associated disease-risk genes, involved in the susceptibility of COVID-19 such as the angiotensin-converting enzyme 2 (ACE2), has recently received considerable attention due to their role in severe injury of lung and mediated SARS-CoV-2 entry as a host receptor. Objectives: Herein, we aimed to systematically review how two main genetic polymorphisms of ACE2 (rs2106809 and rs2074192) can affect the gender susceptibility to SARS-CoV-2 infection. Methods: To conduct this systematic review, a literature search in PubMed, Google Scholar, ScienceDirect, and Nature was made for the period 2004 to 2020. We searched for the impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility. Results: We noticed that there was a differential genotype distribution between males and females in various global populations whereas mutant variants were common in males compared to wild-type variants among females, which may reflect differences in gender susceptibility to infection with SARS-CoV-2. Females are less susceptible to coronavirus as compare to males because of the expression of ACE2 receptor. It has a double role in favour of COVID-19 and against COVID-19. Conclusions: Male mortality is greater than female mortality, which might be attributed to the ACE2 deficiency in women. Epidemiological studies have shown that the differences in sex and age have different susceptibility to SARS-CoV-2 infection.

RETRACTED: Analysis of Conocurvone, Ganoderic acid A and Oleuropein molecules against the main protease molecule of COVID-19 by in silico approaches: Molecular dynamics docking studies

“…Although the vaccine is developed and the population is vaccinated, no specific anti-corona virus molecule has been produced yet. The subjects are being treated with HIV protease inhibitors (ritonavir and lopinavir) in combination with effective antibiotics, or IFNAα-2b inhibitors [ 9 , 10 ] and are limited with multiple side effects, such as anemia, and uncertainty with adequate SARS-CoV-2 antiviral activity [ 11 , 12 ] which suggests identifying the new drug molecule against COVID-19.…”

Inflammatory reflex disruption in COVID‐19

“…After the global outbreak of the COVID-19 pandemic, several experiments showed that the SARS-CoV-2 uses angiotensin-converting enzyme 2 receptor as the receptor to enter the cells. 52,53 However, it might be of great importance to examine other potential interactions between the virus and other cell receptors. There is a great deal of evidence regarding the interactions between SARS-CoV-2 and nicotinic receptors.…”

SARS-CoV-2 triggering autoimmune diseases

“…Over 80 million cases of Covid-19 have been confirmed universally, at a ∼2.2% case fatality rate that mostly happens in the 15-20% of the severe cases of the disease with bilateral interstitial pneumonia (5) . In these cases, acute respiratory distress syndrome (ARDS), characterized by the quick beginning of widespread inflammation in the lungs, is considered as the leading cause of mortality [4] , [6] , [7] , [8] , [9] , [10] .…”